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Crotamine is a highly basic peptide from the venom of Crotalus durissus terriﬁcus rattlesnake. Its common
gene ancestry and structural similarity with the b-defensins, mainly due to an identical disulﬁde bond
pattern, stimulated us to assess the antimicrobial properties of native, recombinant, and chemically
synthesized crotamine. Antimicrobial activities against standard strains and clinical isolates were
analyzed by the colorimetric microdilution method showing a weak antibacterial activity against both
Gram-positive and Gram-negative bacteria [MIC (Minimum Inhibitory Concentration) of 50e>200 mg/
mL], with the exception of Micrococcus luteus [MIC ranging from 1 to 2 mg/mL]. No detectable activity
was observed for the ﬁlamentous fungus Aspergillus fumigatus and Trichophyton rubrum at concentra-
tions up to 125 mg/mL. However, a pronounced antifungal activity against Candida spp., Trichosporon spp.,
and Cryptococcus neoformans [12.5e50.0 mg/mL] was observed. Chemically produced synthetic crotamine
in general displayed MIC values similar to those observed for native crotamine, whereas recombinant
crotamine was overridingly more potent in most assays. On the other hand, derived short linear peptides
were not very effective apart from a few exceptions. Pronounced ultrastructure alteration in Candida
albicans elicited by crotamine was observed by electron microscopy analyses. The peculiar speciﬁcity for
highly proliferating cells was conﬁrmed here showing potential low cytotoxic effect of crotamine against
nontumoral mammal cell lines (HEK293, PC12, and primary culture astrocyte cells) compared to tumoral
B16F10 cells, and no hemolytic activity was observed. Taken together these results suggest that, at low
concentration, crotamine is a potentially valuable anti-yeast or candicidal agent, with low harmful effects
on normal mammal cells, justifying further studies on its mechanisms of action aiming medical and
industrial applications.
 2012 Elsevier Masson SAS. Open access under the Elsevier OA license.ion; AMP, antimicrobial peptide; CPP, cell penetrating peptide; ATCC, American Type Culture Collection; IOC, Oswaldo
0, 50% cytotoxic concentration; TEM, transmission electron microscopy.
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E.S. Yamane et al. / Biochimie 95 (2013) 231e2402321. Introduction agent, with no hemolytic activity and low harmful effects onAll animals, from arthropods to humans, express peptides able to
kill microbial cells. Antimicrobial peptides (AMPs) are essential
components of innate immunity for essentially all organisms,
including invertebrates, vertebrate, and plants, acting as the ﬁrst line
of defense against invading microbes by disrupting cytoplasmic
membrane functions [1]. AMPs are potential candidates for a new
antibiotic generation against multiresistant bacterial strains [2,3].
Interestingly AMPs and cell penetrating peptides (CPPs) are
similar in several aspects: they share physical and chemical char-
acteristics (short length, cationic, amphipathic, and structured
arranged peptides) and, consequently, the fundamental property of
strong interaction with lipid membranes. However, AMPs
predominantly translocate into the cell by transient pore formation
in the membrane, while entry of CPPs has been shown to include
both endocytic and non-endocytic routes [4e6], sometimes
involving more than one single mode [7,8]. Whatever the pathway
CPPs use to translocate membrane (trafﬁcking) systems, they can
serve to deliver molecules into cells and their internal compart-
ments, including endosomes, nuclei, and mitochondria [9e11].
Crotamine is the major toxic component toward rodents found
in the venom of the South American rattlesnake Crotalus durissus
terriﬁcus. It was initially described as being responsible for the hind
limb paralysis observed in mice after venom injection [12]. The
primary structure of crotamine is very similar to those of other
small, non-enzymatic, myonecrotic toxins identiﬁed in different
rattlesnake venoms [13,14]. The 3D structure of crotamine in
solution, determined by proton NMR spectroscopy, showed that
both its cysteine-pairing pattern and global fold are similar to those
of the human b-defensins AMPs, regardless of their low primary
structure identity [15,16]. Our group was the ﬁrst to demonstrate
that crotamine is also a CPP with a high speciﬁcity for actively
proliferating cells [17,18]. We demonstrated that internalization of
this polycationic peptide involves endocytosis and is dependent on
cell membrane heparan sulfate proteoglycans [19]. Subsequently,
we studied the cytotoxic effect of this toxin on highly proliferative
cells and suggested the lysosomes as the primary target for crot-
amine toxic activity at the cellular level [20]. This led us to study
and propose the potential application of native crotamine as
a theranostic agent [18,21].
Crotamine is a highly basic and amphipathic toxin, particularly
rich in Lys, whose 42-residues long polypeptide [YKQCH
KKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG] folds into a
compact structure containing an antiparallel b-sheet and an a-helix
stabilized by three disulﬁde bridges [15,16]. This type of fold and
amphipathic structure is also found in the aforementioned b-
defensins [1,22], which compose the major family of AMPs [23].
Defensins possess direct antimicrobial activities against a broad
range of Gram-negative and Gram-positive bacteria [15,23,24], and
the interaction with glycosaminoglycans was also recently
demonstrated for human b-defensin 2 (HBD2) [25]. Moreover, it
has been suggested that crotamine and b-defensin share a common
ancestry [16,26,27], and a potential antimicrobial activity was
recently attributed to crotamine [28,29].
In the present work we aimed to characterize the antimicrobial
activity of crotamine against Gram-negative and Gram-positive
bacteria, and several fungi species, including clinical resistant
strains. For comparison, recombinant and chemically synthesized
forms of crotamine were included in these studies. In addition,
denatured full-length crotamine and two synthetic linear crot-
amine fragments, comprising half of the positively charged amino
acid residues in each, were also evaluated here. The results indicate
that crotamine has strong potential as an anti-yeast or candicidalnormal mammal cells. The effective antifungal activity against
a number of clinical yeast strains point out the potential of crot-
amine as a structural model compound for the development of
a new generation of antimicrobial drugs against clinical strains,
potentially able to overcome the microbial resistance challenge.
2. Materials and methods
2.1. Materials
C.d. terriﬁcus venom was extracted from snakes maintained at
the Faculdade de Medicina de Ribeirão Preto (FMRP) serpentarium,
São Paulo University, and dried under vacuum. All other chemicals
were from Sigma Chemical Co. (St. Louis, MO, USA). Gomesin was
the same as previously described [30]. The cDNA encoding the full-
length crotamine [GenBank Acc. No. AF044674] subcloned in frame
into the expression plasmid vector pQE-1 (Qiagen, Hilden,
Germany), named 127pQE, was kindly provided by Dr. Gandhi
Rádis-Baptista (Instituto de Ciências do Mar, Universidade Federal
do Ceará, Fortaleza, Brazil).
2.2. Preparation and biochemical characterization of the native,
synthetic, and recombinant crotamine
2.2.1. Puriﬁcation of native crotamine from snake venom
Six hundred milligrams of crude venom were dissolved in 5 mL
of 0.25 M ammonium formate buffer pH 3.5, and the bulk of cro-
toxin, the major venom component, was eliminated by slow speed
centrifugation as a heavy precipitate that formed upon slow addi-
tion of 20 mL of cold water to the solution. Tris-base [1 M] was then
added dropwise to the supernatant to raise the pH to 8.8 and the
solution was applied to a CM-Sepharose FF (1.5  4.5 cm; former
Amersham-Pharmacia, GE Healthcare, Buckinghamshire, UK)
column, equilibrated with 0.04 M TriseHC1 buffer pH 8.8, con-
taining 0.064 M NaCl. After washing the column with 100 mL of
equilibrating solution, crotamine was recovered as a narrow
protein peak by raising the NaCl concentration of the diluting
solution to 0.64 M. The material was thoroughly dialyzed against
water (benzoylated membrane, cut off MW ¼ 3000) and was
lyophilized. Amino acid analysis after acid hydrolysis of a sample
(4 NMeSO3H þ 0.1% tryptamine; 24 h at 115 C) indicated a yield of
72 mg (14.7 mmol) of crotamine and trace amounts of Thr, Ala and
Val (purity > 98%).
2.2.2. Expression of recombinant crotamine in bacteria
The expression and puriﬁcation of the recombinant protein
were performed essentially as previously described [31], except for
the use of NieNTA agarose (Qiagen Inc., Valencia, CA) instead of
glutathione-sepharose beads for crotamine. Brieﬂy, bacteria trans-
formed with 127pQE were grown under antibiotic selection to an
absorbance reading of about 0.6 at 600 nm, when the expression of
recombinant crotamine, carrying a 6xHis-tag at its C-terminus, was
induced by addition of 0.4 mM isopropyl-b-D-thiogalactopyrano-
side (IPTG), followed by incubation for 3 h at 30 C. The bacteria
were then collected by centrifugation, re-suspended in 20 mM
TriseHCl pH 8.5, 100 mM KCl, 20 mM imidazole, 10% (v/v) glycerol
buffer, and then lysed by two cycles of freezing and thawing, fol-
lowed by sonication. After removal of bacterial debris, the super-
natant was puriﬁed by afﬁnity chromatography using NieNTA
magnetic agarose beads, which had been exhaustively washedwith
20 mM TriseHCl pH 8.5, 1 M KCl, 10% (v/v) glycerol buffer, in order
to remove undesired bacterial proteins. The recombinant crotamine
was eluted using 20mM TriseHCl pH 8.5, 100mMKCl, and 100mM
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washing using the centricon YM-3 ﬁlter system (Millipore Corp.,
Billerica, MA, USA), and aliquots of the sample were then analyzed
by SDS/PAGE after quantiﬁcation by Bradford.
2.2.3. Crotamine synthesis
Solid phase chemical synthesis of full-length crotamine
[YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG] was
performed on Boc-Gly-OCH2-PAM resin, using an in-house chem-
istry tailored from the N,N-diisopropylethylamine in situ neutrali-
zation/2-(1H-benzotriazolyl)-1,1,3,3-tetramethyl uroniumhexa-
ﬂuorophosphate activation protocol originally developed by
Schroeder et al. [32]. Speciﬁcally, Boc-amino acids (2.2 mmol)
were activated in dimethylformamide (DMF) for 3 min by
2.0 mmol of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexaﬂuorophosphate (HBTU) in the presence of 20% N,N-diiso-
propylethylamine (DIEA) (v/v), and coupled in stepwise fashion
for 10 min on 0.25 mmol of appropriate PAM resin on an ABI
433A peptide synthesizer. Tri-ﬂuoroacetic acid (TFA) (100%) was
used for removal of N-Boc groups; DMF and dichloromethane
(DCM) were used for batch washes throughout the entire
synthesis. After chain assembly, the peptides were cleaved by
anhydrous hydrogen ﬂuoride in the presence of 5% p-cresol at
0 C for 1 h followed by precipitation with cold ether. All crude
peptides were puriﬁed to homogeneity by preparative C18
reversed phase high performance liquid chromatography (HPLC)
on a Waters Delta Prep 600 system, and the molecular masses
were veriﬁed by a Micromass ZQ-4000 single quadrupole elec-
trospray ionization-mass spectrometer (ESI-MS). Productive
oxidative folding of synthetic crotamine was achieved under
thiol-disulﬁde exchange conditions as previously described
[33,34]. Reduced crotamine was ﬁrst dissolved at 2 mg/mL in
pure water containing 12 mM reduced and 1.2 mM oxidized
glutathione, followed by 4-fold dilution with 0.5 M sodium
bicarbonate (NaHCO3). After overnight stirring at room temper-
ature, the material was puriﬁed to homogeneity by HPLC using
a linear gradient of 10e30% acetonitrile (AcN) containing 0.1%
TFA. The material eluted at the same percent AcN as venom-
derived native crotamine. Pure fractions were veriﬁed by ESI-
MS, and the 6-unit mass reduction was indicative of the forma-
tion of three disulﬁde bridges.
2.2.4. Circular dichroism analysis
Circular dichroism (CD) experiments were carried out using
a Jasco 810 spectropolarimeter (JASCO International Co. Ltd., Tokyo,
Japan), coupled to a Peltier Jasco PFD-425S system for temperature
control. Far UV-CD spectra were collected from 190 to 260 nm and
averaged over 4e8 scans, with a 1 mm path length quartz cell. A
0.5 nm step resolution, 50 nm/min speed, 8 s response time and
1 nm bandwidth were used. The experiments were performed, at
37 C, with 20 mM crotamine in 10 mM TriseHCl pH 7.4. All data
were obtained using three different solutions of the proteins.
2.2.5. Synthesis and puriﬁcation of crotamine fragments
Peptideswere synthesized essentially as previously described by
Picolo and co-workers [35]. Brieﬂy, the syntheses of P1 (Crot2e18
[KQSHKKGGHSFPKEKIS]) and P2 (Crot27e39 [KMDSRWRWKSSKK])
were carried on an automated PSSM-8 peptide synthesizer (Shi-
madzu Corp., Kyoto, Japan) by a stepwise solid-phase method using
N-9-ﬂuorenylmethoxycarbonyl (Fmoc) chemistry (Novabiochem-
EMD Chemicals Inc., San Diego, CA, USA). All the resins and Fmoc-L-
amino acids were purchased from Nova Biochem (UK). Cleavage of
the peptide from the resin was achieved by treatment with
a mixture of TFA/1,2-ethanedithiol/ethyl methyl sulﬁde for 2 h at
room temperature. After removal of the resin by ﬁltration andwashing twicewith TFA, the crude synthetic peptidewas puriﬁed by
preparative reversed-phase HPLC (Shimadzu Corp.) on a YMC-Pack
ODS column (20mm 150mm) (YMC Co. Ltd., Shimogyo-ku, Kyoto,
Japan), using a linear gradient from 3 to 20% AcN in 0.1% TFA, at
a ﬂow rate of 7 mL/min. Both, the homogeneity and the sequence of
each synthetic peptide were conﬁrmed by analytical HPLC and
MALDI-TOF mass spectrometry (Amersham Biosciences, Uppsala,
Sweden). The amino acid sequence of the peptides was analyzed by
a gas-phase sequencer PPSQ-10 (Shimadzu Corp.) based on auto-
mated Edman degradation. All mass spectra were acquired on
a Voyager Elite MALDI-TOF MS spectrometer (Applied Biosystems,
Framingham, MA, USA), equipped with a delayed extraction system
and 337 nm pulsed nitrogen laser. The accelerating voltage was
20 kV. Argon gas was used as the collision gas for the CID/PSD
experiment. A matrix, a-cyano-4-hydroxycinnamic acid was
prepared at a concentration of 10 mg/mL in 1:1 AcN/0.1%TFA.
2.2.6. Denaturation of native crotamine
Aiming to test the impact of the three dimensional structure on
the functional properties of puriﬁed crotamine, the disulﬁde bonds
were reduced by incubation either at 100 C with 5 mM dithio-
threitol or 10 mM b-mercaptoethanol for 10 min, or by autoclaving
1mg/mL crotamine solution in purewater at 100 C for 20min [29].
Then CD experiments were then carried out, as described above, to
conﬁrm the denaturation of crotamine, after these protein-
denaturing treatments andbeforecarryingout the functional assays.
2.3. Antibacterial and antifungal susceptibility tests
2.3.1. Microorganisms
The microorganisms used in this study are from the American
Type Culture Collection (ATCC), clinical isolate strains from the
Microbiology Department of São Paulo Federal University (São
Paulo, SP, Brazil) and from Adolfo Lutz Institute (São Paulo, SP,
Brazil). Clinical strains deposited at Oswaldo Cruz Institute Collec-
tion (IOC) were coded by IOC numbers, as indicated for each strain.
Themicroorganisms used in this studyare the following: Escherichia
coli [ATCC 25922], Staphylococcus aureus [ATCC 29213], Pseudo-
monas aeruginosa [ATCC 29213], Cryptococcus neoformans [ATCC
90112], Candida albicans [ATCC 36802/IOC 3704], C. albicans IOC
4558, Candida krusei [IOC 4559], Candida glabrata [IOC 4565],
Candida parapsilosis [IOC 4564], Candida tropicalis [IOC 4560],
Candida guilliermondii [IOC 4557], C. neoformans [IOC 4528], Asper-
gillus fumigatus [IOC 4526], Trichophyton rubrum [IOC 4527], and
Trichosporon spp. [IOC 4569]. Other microorganisms also used here
are: C. neoformans [IOC 4528] (clinical strain), E. coli [SBS363], and
Micrococcus luteus (A270) from Pasteur Institute Collection (Paris,
France); C. albicans (MDM8) from the Microbiology Department
Collection, Biomedical Sciences Institute of São Paulo University
(São Paulo, SP, Brazil), and C. tropicalis (Squibb 1600, L. 03/97) from
Adolfo Lutz Institute Culture Collection (São Paulo, SP, Brazil).
The isolates were identiﬁed by standard methods [36] and were
preserved at 80 C. Prior to testing, each isolate was subcultured
at least twice on Sabouraud dextrose agar (Himedia, Biosystems
Com. Imp. Exp. Produtos Lab. Ltda, Curitiba, PR, Brazil) to ensure
optimal growth characteristics.
2.3.2. Minimal inhibitory concentration (MIC)
The antibacterial and antifungal activities were monitored by
a microbial growth inhibition assay in liquid medium as described
earlier [37,38]. Brieﬂy, 10 mL of the peptide solution were added to
90mL of a suspensionof amid-logarithmicphase culture of bacteria at
a startingOD595 nm¼ 0.001 inpoor broth nutrientmedium (PB: 1.0 g
peptone in 100 mL of water containing 86 mM NaCl at pH 7.4;
217 mOsM). In the case of the antifungal activity the medium used
Fig. 1. Analysis of the native and recombinant crotamine by SDS/PAGE and Western
blotting (WB). Aliquots of the recombinant (lanes 1 and 2) and native crotamine (lane
3) were analyzed by 12.5% SDS/PAGE electrophoresis stained with Coomassie Brilliant
Blue (SDS/PAGE, A), and by Western blotting (WB, B) using primary antibody against
crotamine. Twenty times less of each sample was used for the WB analysis compared
to the SDS/PAGE.
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of H2O at pH 5.0; 79 mOsM). Microbial growth was measured by
monitoring the OD increase at 595 nm. The minimal inhibitory
concentration (MIC) is the lowest concentration that caused 100%
growth inhibition determined by optical density measurements in
amicroplate reader (VICTORMultilabel Plate Reader, PerkineElmer),
following incubation at 30 C for 18 h in an orbital shaker for
microplate (Titramax 100, Heidolph Instruments). The MIC was
recorded as the aeb mM range, where “a” corresponds to the highest
concentration in which the bacterial growth was observed and “b”
corresponds to the lowest concentration of the peptide that caused
100% of inhibition microbial growth. The natural peptide gomesin is
a well-studied antimicrobial peptide (AMP) from hemocytes of the
spider Acanthoscurria gomesiana with antimicrobial activity against
both Gram-positive and Gram-negative bacteria, and for this reason
gomesin was used here as a positive control.
2.3.3. Fungicidal assay
Fungicidal activity assays for crotamine were conducted in trip-
licate, using the following clinical yeast isolates: C. albicans [IOC
4558], C. krusei [IOC 4559], C. glabrata [IOC 4565], C. parapsilosis [IOC
4564], C. tropicalis [IOC 4560], C. guilliermondii [IOC 4557], and Tri-
chosporon spp. [IOC 4569]. The clinical isolates (ﬁnal concentration
of 104 cells/mL) were suspended in a growth medium containing
1.2%potatodextrose (w/v) (Difco; “half strength”). EightymL aliquots
of this suspension were dispensed into wells of a microplate con-
taining20mL ofwater or crotamine [4MIC], andwere incubated for
24 h at 30 C. The same culture without crotamine was the control.
After incubation, 20 mL of crotamine-treated and control (water)
culture were removed and sown in Petri dishes containing nutrient
agar [Luria-nutrientmedium Bertani: 1% Bacto-Tryptone, 0.5% yeast
extract, 1% NaCl, and 1.5% (w/v) agar]. The kinetics of killing assay
induced by crotamine was monitored. This procedure, slightly
modiﬁed of Klepser et al. [39], was performed only against the
clinical isolateC. albicans [IOC4558],whichwebelieve to potentially
reﬂect the expected effects on nosocomial strains. After different
incubation times (10 min, 1, 2, 4, 8, 12, and 24 h), 20 mL aliquots
samples were collected and sown in Petri dishes with Sabouraud
dextrose agar. The number of Colony Forming Units (CFU), which
represents the viable colony counts, was determined the following
morning, to ensure optimal growth of all viable entities. Results
were presented as the mean  SD of triplicates.
2.4. Ultrastructural analysis of C. albicans cells treated with
crotamine
2.4.1. Transmission electron microscopy (TEM)
This methodology was adapted from that used by Bizerra et al.
[40]. Initially, cells treated for 24 h with crotamine [10 or 25 mM,
corresponding to 50 or 125 mg/mL] or gomesin [10 mM, i.e. 22.7 mg/
mL] were washed in PBS and ﬁxed overnight at 4 C with 2.0%
formaldehyde plus 2.5% glutaraldehyde buffered at pH 7.2 with
0.1 M sodium cacodylate. The ﬁxed cells were post-ﬁxed in 1%
osmium tetroxide for 1 h at room temperature. After dehydration in
a graded series of ethanol and treatment with propylene oxide, the
cells were embedded in Epon resin. Ultrathin sections (60 nm)were
contrasted with uranyl acetate and lead citrate, and they were
examined using a transmission electron microscope (JEOL, JEM-
1200EX II, JEOL Ltd., Tokyo, Japan).
2.5. Cytotoxicity assay
2.5.1. Hemolytic assay
Fresh citrated human blood obtained from a healthy volunteer
donor was used in this assay. The hemolytic activity assay wasmonitored against human erythrocytes. Serial dilutions of native
crotamine [0.1e100 mM] were incubated in microcentrifuge tubes
with a suspension of erythrocytes (0.4%) in phosphate-buffered
saline (NaCl 0.14 M; KCl 2.7 mM; Na2HPO4 10 mM; KH2PO4
1.8 mM pH 7.4). As a positive control (100% lyses), erythrocytes
were incubated with 0.1% Triton X-100. After 1 h at 37 C, the
samples were centrifuged (320 g, 5 min), and the absorbance of
the supernatant (50 mL) was measured at 405 nm using a microtiter
plate reader.
2.5.2. Viability test
Cell viability after exposure to crotaminewas examined using the
MTT assay, whereby metabolically active mitochondrial dehydroge-
nases convert the tetrazolium salt MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide; Sigma Chemical Co., St.
Louis, MO, USA) to insoluble purple formazan crystals at 298 nm,
which was proportional to cell viability. Primary culture of mice
astrocyte cells, rat pheochromocytoma PC12 cells, embryonic kidney
HEK293 cells, and tumoral mice melanoma B16F10 cells were used
for cytotoxicity analysis of crotamine. Cells were plated in 96-well
microtitre plates at 2  105 cells/mL. After overnight incubation,
the medium was removed and the cells were incubated with
appropriate amounts of toxin in the presence of 100 mL of appro-
priate culturemedia supplementedwith 10% of FBS for 24 h, at 37 C,
in an atmosphere of 5% CO2 in air. At the end of incubation 20 mL of
MTT solution (5 mg/mL in PBS) were added to each well. After 4 h,
100 mL of 0.04 N HCl in isopropanol were added to each well and
thoroughly mixed before the plate was read on a FlexStation3
(Molecular Devices, Sunnyvale, CA, USA, www.moleculardevices.
com), using a test wavelength of 570 nm and a reference wave-
length of 620 nm (MTT viability assay). Percent of cytotoxicity was
calculated as 100 (1 [optical density at 570e620 nmwith toxin]/
[optical density at 570e620 nm without toxin]). Results are
expressed as mean values  SD of three independent experiments,
and the 50% cytotoxic concentration (CC50) was estimated as previ-
ously [20].
3. Results
3.1. Expression and puriﬁcation of recombinant crotamine and
immunochemical characterization
Fig. 1A shows the SDS/PAGE analysis of recombinant protein
after single step puriﬁcation using NieNTAmagnetic agarose beads
afﬁnity chromatography. As assessed by the SDS/PAGE, the
recombinant proteins yielded an apparently homogenous protein
sample of about>95% purity whichmigrated similarly to the native
crotamine (Fig. 1A). In order to further conﬁrm the identity of the
obtained recombinant crotamine, Western blotting experiments
were carried out using rabbit polyclonal anti-crotamine antibody,
showing the recognition of one single band of about 5 kDa for both
native and recombinant crotamine (Fig. 1B).
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The circular dichroism (CD) spectra of native, synthetic, and
recombinant crotamine are shown in Fig. 2. The overall CD spec-
trum was similar to native and synthetic crotamine (Fig. 2), sug-
gesting overall similar secondary structure for both. The a-helical
contribution was signiﬁcant for both native and synthetic crot-
amine, as observed in the CD spectrum (Fig. 2). On the other hand,
the CD spectrum of the recombinant crotamine was more charac-
teristic of a disordered peptide chain (Fig. 2). In the same way, the
CD analysis of denatured native crotamine also showed a spectrum
typical of a disordered structure independent of the denaturing
protocols employed, i.e., heating in the presence of 5 mM DTT or
10 mM b-mercaptoethanol, or by autoclaving 1 mg/mL crotamine
solution in water (Supplementary Figure S1).
3.3. Antimicrobial susceptibility tests of bacterial and fungal
standard strains
The MIC values of native, synthetic, and recombinant crotamine,
as well as those for the derived small peptides P1 and P2, are shown
in Table 1. The reliance upon suchmeasurements was guaranteed by
using gomesin, which showed an effective antibacterial activity
against Gram-positive and Gram-negative bacteria strains in our
hands, exactly as previously described [30]. Although gomesin
clearly displayed efﬁcient antimicrobial activity against Gram-
positive and Gram-negative bacteria, in general no signiﬁcant
activity could be observed for either native, synthetic or recombinant
crotamine [MIC values >200 mg/mL], except for E. coli (SBS363) that
showed MIC values ranging from 12.5 to 25.0 mg/mL (Table 1).
Peptide P2 also showed MIC values ranging from 17 to 34 mg/mL for
Gram-negative bacteria P. aeruginosa [ATCC 29213] (Table 1).
Another exception was for the Gram-positive bacteria M. luteus
(A270), in which both native crotamine and gomesin showed MIC
values ranging from 1 to 2 mg/mL (Table 1). Nevertheless, for this
same strain, the recombinant crotamine showed a stronger potency
compared to native crotamine, with MIC values between 0.25 and
0.50 mg/mL. Short peptide analog P1 showed no activity up to 25 mg/
mL, while P2 showed MIC values ranging from 5 to 10 mg/mL for the
Gram-positive bacteria M. luteus (A270) (Table 1).
In contrast, signiﬁcant antifungal activity was observed against
all reference yeast strains tested, including C. albicans [MDM8 andwavelength (nm)



















Fig. 2. CD spectra proﬁle of the native, synthetic and recombinant crotamine. Circular
dichroism (CD) spectra of native (B), full-length synthetic (C) and recombinant (,)
crotamine is shown.ATCC 36802] and C. neoformans [ATCC 90112] strains, with MIC
values around 15e30 mg/mL for native crotamine. Interestingly, the
MIC values of C. albicans strain MDM8 for the recombinant
crotamine were signiﬁcant lower [between 0.5 and 1.0 mg/mL]
when compared to those obtained with the native toxin [15e
30 mg/mL] (Table 1). Although linear unstructured reduced crot-
amine showed activity against C. albicans (MDM8 strain) in the
range of 0.5e1.0 mg/mL, the small linear peptides analogs P1 and P2
showed no activity up to 25 mg/mL (Table 1). However, these linear
peptides analogs showed similar MIC values [6e12 mg/mL]
compared to those observed for the denatured native crotamine
[6e12 mg/mL] (Supplementary Table 1), while structured native
crotamine MIC values [15e30 mg/mL] against C. neoformans [ATCC
90112] was signiﬁcantly higher (Table 1).
3.4. Antifungal susceptibility of clinical yeast isolates
Table 2 summarizes the in vitro susceptibilities of clinical yeast
isolates to native, synthetic and recombinant crotamine, as well as
to peptide analogs P1 and P2.
The MIC values obtained with native, synthetic, and recombi-
nant crotaminewere below 50 mg/mL for all tested yeasts, including
Candida spp., Trichosporon spp., and C. neoformans strains, with an
exception for synthetic crotamine that showed a little higher MIC
values ranging from 50 to 100 mg/mL only for C. guilliermondii [IOC
4557]. The antifungal activity of synthetic crotamine was generally
very similar to that observed with the native molecule. The only
exceptions were for Trichosporon spp. and C. guilliermondii isolates,
with lower and higher MIC values, respectively, for synthetic
compared to native crotamine (Table 2). Excluding these two
isolates from the analysis, the MIC values obtained with both
synthetic and native crotamine were almost the same, i.e. ranging
from 12.5 to 50.0 mg/mL (Table 2).
Interestingly, overall the MIC values obtained with recombinant
crotamine [1.5e6.0 mg/mL] were about ten times lower than that
for native crotamine [12.5e50.0 mg/mL] for most clinical strains
evaluate here, with the single exception of C. krusei isolate, which
showed exactly the same MIC values for both native and
recombinant molecules [12.5e25.0 mg/mL]. These results show
that recombinant crotamine exhibits a higher antifungal activity
for almost all the yeast strains evaluated here (Table 2), demon-
strating that the unstructured crotamine (Fig. 2) is a more efﬁcient
antifungal agent than the structured native crotamine, although the
linear short peptide analogs were overall less efﬁcient.
Although crotamine exhibits signiﬁcant antifungal activity
against the medically important yeast species, no major activity
could be observed against the ﬁlamentous fungus A. fumigatus [IOC
4526] and T. rubrum [IOC 4527] for native crotamine and its linear
fragment peptides P1 and P2, even at concentrations up to 125 and
100 mg/mL, respectively (Table 2).
Peptides P1 and P2 did not show any important antifungal
activity, with the exception of the clinical strain C. neoformans [IOC
4528] and C. krusei [IOC 4559], which exhibited MIC values between
6 and 12 mg/mL and 35e70 mg/mL, respectively. In addition, peptide
P2 showed MIC values of 35e70 mg/mL and 10e20 mg/mL for
Trichosporon spp. [IOC 4569] and C. guilliermondii [IOC 4557]
strains, respectively (Table 2).
3.5. Fungicidal effect of crotamine
The fungicidal activity of crotamine against the most important
yeast species, including C. albicans [IOC 4558], C. krusei [IOC 4559],
C. glabrata [IOC 4565], C. parapsilosis [IOC 4564], C. tropicalis [IOC
4560], C. guilliermondii [IOC 4557], and Trichosporon ssp. [IOC 4569]
was also evaluated. Exponential phase culture of these yeast strains
Table 1
Crotamine minimum inhibitory concentrations (MICs) values for bacterial and fungal standard strains.
Organisms Minimum inhibitory concentration [mg/mL]
Native P1 P2 Synthetic Recombinant Gomesin
Gram-negative bacteria
Escherichia coli [SBS363] 12.5e25.0 >80 >80 >200 NDa 1e2
Pseudomonas aeruginosa [ATCC 29213] >200 >80 20e40 >200 >200 6e12
Gram-positive bacteria
Staphylococcus aureus [ATCC 29213] >200 >80 >40.0 >200 >200 3e6
Micrococcus luteus (A270) 1e2 NDa,b 6e12 NDa 0.25e0.50 1e2
Fungus
Candida albicans (MDM8) 15e30 NDa,b NDa,b NDa 0.5e1.0 0.3e0.6
Candida albicans [ATCC 36802] 15e30 >100 >100 NDa NDa 12e24
Cryptococcus neoformans [ATCC 90112] 15e30 6e12 6e12 NDa NDa NDa
MDM8: USP Microbiology collection (SP, Brazil).
ATCC: The Global Bioresource Center (USA).
A270: CNRS (France).
a ND ¼ non determined.
b ND ¼ non observed up to 25 mg/mL.
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200 mg/mL] of native crotamine. Under this condition no CFU were
detected for all evaluated yeast strains (Table 3). In agreement with
the CFU count data, the kinetics of C. albicans IOC 4558 killing in the
presence of 4-fold MIC concentration conﬁrmed the fungicidal
activity of crotamine. A complete cell killing was observed even at
short incubation times, as early as 10 min (Fig. 3).
3.6. Ultrastructural alterations induced by crotamine
Aiming to further investigate the effect of crotamine on
C. albicans IOC 4558, the morphology and ultrastructure of these
cells were analyzed by transmission electron microscopy (TEM)
(Fig. 4). Untreated cells had both a normal cytoplasmmembrane and
cell wall morphology (Fig. 4A). By means of conventional TEM, we
observed that control cells exhibited a cell wall with two layers: i) an
electron-dense outer layer; and ii) an inner layer of low electron
density, continuous with the plasma membrane. On the other hand,
incubation of C. albicans [IOC 4558] yeast cells for 24 h in the pres-
ence of 50 or 125 mg/mL [corresponding to10 or 25 mM] of crotamine
resulted in pronounced ultrastructure alterations (Fig. 4B and C,
respectively). Cells tended to adopt irregular shapes and the cell wall
became irregular in the layering structure with predominance of
a more electron-dense layer (Fig. 4B). Plasma membranes lost their
integrity and cytoplasm contents coagulated. Similar alterations
were observed for treatments with gomesin (Fig. 4D).
3.7. Cytotoxicity effect of crotamine
Interestingly, no hemolytic activity against human erythrocytes
was observed for native crotamine (triplicate) at concentrations upTable 2
Antifungal susceptibility of clinical isolates determined by a colorimetric broth microdilu
Clinical fungus strains Minimum inhibitory concentratio
Native P1
Candida krusei [IOC 4559] 12.5e25.0 40e80
Trichosporon spp. [IOC 4569] 12.5e25.0 >80
Candida glabrata [IOC 4565] 25e50 >80
Candida albicans [IOC 4558] 25e50 >80
Candida parapsilosis [IOC 4564] 25e50 >80
Candida tropicalis [IOC 4560] 12.5e25.0 >80
Candida guilliermondii [IOC 4557] 12.5e25.0 >80
Cryptococcus neoformans [IOC 4528] 15e30 6e12
Aspergillus fumigatus [IOC 4526] >125 >100
Trichophyton rubrum [IOC 4527] >125 >100
IOC - Instituto Oswaldo Cruz.to 100 mM (Fig. 5). For comparison, gomesin, the antimicrobial
peptide from hemocytes of the A. gomesiana spider, displays
a certain degree of hemolytic activity, viz., 29% of cell lysis at
100 mM, as previously described [30].
In addition, to further evaluate the cytotoxic effect of crotamine,
several normal cell lines including mice astrocyte primary culture
cells, rat pheochromocytoma PC12 cells, embryonic kidney HEK293
cells, and tumoral mice melanoma B16F10 cells were treated with
different concentrations of crotamine [0, 50, 100, and 250 mg/mL].
Then the cell viability was examined using the MTT (tetrazolium
salt 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide)
assay, in which metabolically active mitochondrial dehydrogenase
activity converts the MTT to insoluble purple formazan crystals
at a rate proportional to cell viability (Fig. 6). The 50% cytotoxic
concentration (CC50) was above 250 mg/mL for all cells lines tested,
except for the tumoral B16F10 cells, which was found to be around
2 mM [w10 mg/mL], as already described by us elsewhere [20].4. Discussion
Antimicrobial peptides (AMPs) are important functional mole-
cules in innate immunity, and provide a sophisticated ﬁrst line of
host defense with the capacities to kill microbes directly, and to
stimulate innate and adaptive defense systems [23,41,42]. In the
case of the human defensins, there is direct evidence for a correla-
tion between this polypeptide’s expression and the incidence of
infection [24,43e45].
The three-dimensional structure of crotamine in solution indi-
cates that both the cysteine-pairing pattern and the global fold of
this toxin are similar to those of the AMP human b-defensin [15,16].














Fungicidal activity of crotamine at concentrations 4 MIC values against yeast
clinical strains.





Candida krusei [IOC 4559] 12.5e25.0 100 0
Trichosporon spp. [IOC 4569] 12.5e25.0 100 0
Candida glabrata [IOC 4565] 25.0e50.0 200 0
Candida albicans [IOC 4558] 25.0e50.0 200 0
Candida parapsilosis [IOC 4564] 25.0e50.0 200 0
Candida tropicalis [IOC 4560] 12.5e25.0 100 0
Candida guilliermondii [IOC 4557] 12.5e25.0 100 0
E.S. Yamane et al. / Biochimie 95 (2013) 231e240 237gomesiana spider gomesin has been characterized. Human b-
defensins exhibit antimicrobial activity against Gram-positive and
Gram-negative bacteria [23,24,45,46]. Gomesin also has potent
antimicrobial activity against the same bacterial species [30].
However, each animal species seems to possess numerous paralo-
gous b-defensin genes, which have arisen by multiple duplication
events followed by bursts of sequence variation [47]. The human b-
defensins are a unique and diverse group of molecules displaying
a characteristic triple-stranded twisted antiparallel b-sheet scaf-
fold, whose formation seems to depend primarily on the presence
of conserved disulﬁde bridges, but presenting few residues
conserved in their sequences [47], with an extensive and distinct
set of biological activities [48].
In this study, we describe for the ﬁrst time an extensive analysis
of the antimicrobial and antifungal activities of native, chemically-
synthesized, and expressed recombinant crotamine. Although the
impressive low MIC value observed for the Gram-positive bacteria
M. luteus (A270), the antibacterial activity of crotamine and its
analogs against most Gram-negative and Gram-positive strains
studied here (Table 1) was unremarkable compared to those
observed for gomesin and b-defensins. Likewise, no activity could
be observed against S. aureus (also Gram-positive) at concentra-
tions up to 200 mg/mL (Table 1), in contrast to that described for
human defensin 5 [49]. These results conﬁrm that crotamine
exhibits a narrow spectrum of antibacterial activity, compared to
the broad activity of human b-defensins [23,24,45,46]. Since
M. luteus is the major microbial contaminant of orthodontic buccal
devices and oral dispensers [50,51], further exploitation ofTime (min)
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Fig. 3. Kinetics of C. albicans IOC 4558 killing by crotamine. Crotamine (200 mg/mL,C)
was added to a 104 culture of C. albicans. As control the same culture without crot-
amine was utilized (B). Aliquots were removed at various times, and the number of
colony forming units (CFU) was determined on LB agar plates after overnight incu-
bation at 30 C.crotamine and its analogs activities against this bacterial species is
warranted.
In contrast to the weak antibacterial effects, crotamine and its
analogs were found to exhibit signiﬁcant antifungal activity. In
general, synthetic and native crotamine showed similar antifungal
activity against all yeast clinical strains, including Candida species,
C. neoformans, and Trichosporon spp.
Recently, two studies described the antibacterial activity of
crotamine [28,29], and both studies suggested a crotamine activity
against only a narrow spectrum of bacteria. Yount et al. [28] sug-
gested an antifungal activity of crotamine against C. albicans
isolates. However, these authors used a radial diffusion method-
ology in which MIC values cannot be evaluated. Oguiura et al. [29]
reported that crotamine exhibited antibacterial activity only
against E. coli isolates [ATCC 25922], with MIC values ranging from
25 to 100 mg/mL [5e20 mM], while no antimicrobial activity was
observed with P. aeruginosa, Salmonella typhimurium, S. aureus,
and Listeria monocytogenes isolates. These results are in good
agreement with our data presented here. However, in our study
the MIC values were estimated by the microdilution test, and also
the antifungal activity of crotamine was evaluated using three
yeast standards and 10 clinical isolates, including eight yeast
species and two ﬁlamentous fungi. Interestingly, a very potent
antifungal activity was observed for native crotamine against all
yeast strains evaluated here. However, this toxin did not exhibit
antifungal activity against the ﬁlamentous fungus A. fumigatus
[IOC 4526] and T. rubrum [IOC 4527] (Table 2). Crotamine peptide
fragments P1 and P2 did not show signiﬁcant antifungal activity
against the clinical strains studied here, with the exception for
standard microbiological and clinical strains of C. neoformans [ATCC
90112/IOC 4528] with MIC values around 6e12 mg/mL (Tables 1 and
2). Activities with MIC values around 40e80 mg/mL were also
observed for these peptides against C. krusei [IOC 4559] and
Trichosporon spp. [IOC 4569], although for the latter no activity
was observed for P1 up to 80 mg/mL (Table 2). Note that the MIC
value for P2 [about 20 mg/mL] against C. guilliermondii [IOC 4557]
was very close to that observed for native crotamine [12.5e25 mg/
mL] (Table 2).
In summary the results presented here show that recombi-
nant crotamine exhibits a higher antifungal activity for almost all
the yeast strains evaluated here (Tables 1 and 2), demonstrating
that the unstructured crotamine is a more efﬁcient antifungal
agent than the structured native crotamine, as also indicated by
the use of denatured native crotamine (Supplementary material),
although the linear short peptide analogs were overall less
efﬁcient.
The MICs of recombinant crotamine observed for several stan-
dard and clinical strains were generally lower than those of native
crotamine (Tables 1 and 2). We believe that our bacterially-
expressed recombinant crotamine represents the features of
a completely reduced/linear crotamine, as conﬁrmed by its CD
spectrum (Fig. 2). Enhancement of antimicrobial activity by
reduction of disulphide bonds has been described for human b-
defensin 1 [32]. In addition, reduction of these bonds alters the
structure of natural b-defensin, resulting in a different type of
membrane interaction and a switch to different modes of action
toward microbial cells underlying the antimicrobial activity [53].
Covalent dimerization via SeS bond formation could enhance such
activity [53]. On the other hand, disulﬁde bond deletion in human
defensin 5 disulﬁde array mutants showed an attenuation of anti-
bacterial activity against S. aureus [49]. Recombinant mouse b-
defensin 3 (the human homolog of b-defensin 2) was shown to
present most signiﬁcant antifungal activity against ﬁlamentous
species compared to yeast forms, with a mild antibacterial activity
[54]. Clearly, the nature and extent of SeS bond formation has
Fig. 6. Cytotoxic effect of crotamine. Primary culture of mice astrocyte cells, rat
pheochromocytoma PC12 cells, embryonic kidney HEK293 cells and tumoral mice
melanoma B16F10 cells were incubated with 0, 50, 100 and 250 mg/mL of crotamine for
24 h, and the cell survival rate was measured by the MTT assay. The percentage of cell
growth in the control group was designated as 100%. Results are expressed as mean
values  SD of three independent experiments.
Fig. 4. Transmission electron micrographs of C. albicans cells treated with crotamine. (A) Untreated cells exhibited a normal plasma membrane and cell walls with two layers, an
electron-dense outer layer and an inner layer of low electron density (arrows black and white, respectively). (B and C) The yeast cells treated with 50 and 125 mg/mL, corresponding
to 10 and 25 mM of crotamine, respectively, exhibited pronounced morphological alterations, including membrane collapse (black-headed arrows), cell wall with predominance of
the more electron-dense layer (white-headed arrows) and cytoplasm coagulation. Similar alterations were observed when crotamine was replaced by gomesin (D). Scale
bars ¼ 1 mm.
Concentration [µM] 
























Fig. 5. Hemolytic assay. Crotamine (C) and gomesin (B) were incubated with human
erythrocytes at concentrations ranging from 0.1 to 100 mM for 1 h at 37 C. The
hemolysis percentual was expressed in relation to a 100% lysis control (erythrocytes
incubated with 0.1% Triton X-100).
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area that requires further exploration.
In addition to the antifungal activity analysis of crotamine, we
also evaluated the fungicidal activity of this toxin. The kinetics of
C. albicans IOC 4558 killing by 4-fold MIC crotamine showed
complete cell killing after only 10min incubation (Fig. 3). Moreover,
addition of 4-fold MIC of native crotamine to exponential phase
cultures of several clinical yeast strains showed a major fungicidal
effect after overnight incubation, with no CFU detected on LB agar
plates (Table 3). Since the majority of antifungal drugs currently
used for treatment of Candida species, Trichosporon spp., and
C. neoformans fungal infections are usually fungistatic [5,52], the
fungicidal activity of crotamine is an important improvement in
relation to these other currently used drugs.
With respect to the ultrastructural alterations in cells treated
with crotamine, we showed that C. albicans IOC 4558 cells sub-
jected to 10 and 25 mM crotamine, which correspond to 50 and
125 mg/mL, respectively, exhibited pronounced morphological
alterations, including membrane collapse and cytoplasm coagula-
tion, which were very similar to the changes observed with spider
gomesin (Fig. 4). Our results lead to the conclusion that crotamine
antifungal activity is related to disruption of the cytoplasm
membrane of fungal cells. In contrast to gomesin, native crotamine
did not show hemolytic activity (Fig. 5), and showed high values for
50% cytotoxic concentration [CC50 > 50 mM] when tested against
non-tumoral animal and human cells (Fig. 6).
These results strongly suggest that crotamine has potential use
as a novel antifungal agent. The Candida species, predominantly
C. albicans, are involved in a wide range of human infections,
including invasive candidiasis, oral, and vulvovaginal infection [55].
The broad antifungal activity and the pronounced activity against
the Gram-positive bacteriaM. luteus (A270) observed for crotamine
in this work open new perspectives for the use of this venom
component in infectious disease treatments. The demonstrated
successful production of crotamine by chemical synthesis or
recombinant expression with biological activity further reinforces
the potential feasibility of using this molecule in medical and
industrial applications.5. Conclusion
In conclusion, we have shown in this work that crotamine has
effective antifungal activity against a number of clinical yeast
strains, with great potential to contribute to the development of
a newgeneration of antimicrobial compounds able to overcome the
microbial resistance challenge. We envision new perspectives for
the use of this venom component in biomedicine, as it has been
described for a number of other natural toxins [56].Acknowledgments
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